Air turbulence: When can it become dangerous?
Flight turbulence like that encountered by a Singapore Airlines flight on Tuesday is extremely common, but there's one aspect of severe turbulence an aviation expert says can lead to serious injury.
Biopharmaceutical company Medicago and drug maker GlaxoSmithKline reported Tuesday positive efficacy and safety results from the Phase 3 trial of their plant-based COVID-19 vaccine.
Medicago, which is headquartered in Quebec, reported in a news release that their Phase 3 placebo-controlled study -- conducted in more than 24,000 subjects in six countries who are 18 and older -- reported an overall vaccine efficacy rate of 71 per cent against all variants of SARS-CoV-2 which were circulating at the time of the study.
“Vaccine efficacy was demonstrated in an environment dominated by SARS-CoV-2 variants unlike most published Phase 3 efficacy trials for currently licensed COVID-19 vaccines that were conducted when only the ancestral virus was circulating,” the release states.
In an interview with CTV News, Executive Vice-President of Innovation Development and Medical Affairs for Medicago, Marc-Andre D’Aoust, said the study ended up being focused entirely on COVID-19 variants.
“In our efficacy analysis, we have not seen any cases of the original strain of COVID-19…so the results show the vaccine is efficacious against all of those variants we have observed during the study,” he said.
The vaccine uses plant-based technology to create “virus-like particles,” (VLP) which are designed to mimic the structure of viruses so that the immune system can recognize them and build an antibody response to them. VLP do not contain core genetic materials, which makes them non-infectious and unable to replicate.
D’Aoust said it only takes Medicago “days” to produce the vaccine from the moment they have the virus sequence in researchers’ hands.
“So for a new virus, for example, once we have the sequence, in 19 days, we've found that we can produce a research-grade VLP which is the structure of the vaccine that we're using…from there, we can continue with the development and that's what we did for the COVID-19 vaccine development early in 2020,” he explained.
Medicago’s vaccine demonstrated 75.3 per cent efficacy against COVID-19 of any severity for the Delta variant, which D’Aoust said is the most widely circulated strain, and 88.6 per cent efficacy against the Gamma variant.
A small number of severe cases of COVID-19 were observed in the study, but none occurred in the vaccinated group, Medicago said in the release.
“These results are great, these results show the vaccine is efficacious,”D’Aoust said. “We’ve developed [our] technology for 20 years now, and over the last two years we’ve developed a COVID-19 vaccine and these results show that the plant-based platform that we have used to produce the vaccine can produce an efficacious vaccine.”
No cases of the Alpha, Lambda, or Mu variants were observed in the vaccinated group while 12 cases were observed in the placebo group, the release states.
The Omicron variant was not circulating during the study, but D’Aoust said in the interview that Medicago is already analyzing the new strain.
“We're currently evaluating the cross reactivity of the antibodies raised by our current vaccine against Omicron,” he said, adding that the company has “taken action” in case a change is needed in their vaccine in light of the variant.
The Phase 3 study reported no serious adverse events and reactions were “generally mild to moderate and transient,” with symptoms lasting on average from one to three days.
The full results of the Phase 3 study will be released in a peer-reviewed publication, and Medicago will “imminently” seek Health Canada approval based on the Phase 3 results as part of its rolling submission.
“If approved by authorities, this vaccine will be the first plant-based vaccine to be used in humans,” D’Aoust said. “We’re very proud…[because] it will also be the first vaccine to be developed in Canada.”
Professor of Virology and Immunology at Memorial University Nfld., and Vice President of the Canadian Society for Virology Rod Russell told CTV News in an interview Monday that he was not surprised at news of Medicago’s positive results.
“It’s really good that this is an alternative…I like the idea that it’s a different type of platform [plant-based] which is good for hesitancy,” Russell said. “We’re going to need different vaccines or a range of vaccines…so my reaction to the trial data is encouraging.”
Russell noted that Canada “experienced a delay” in access to vaccines at the beginning of the pandemic partly because none were being made domestically.
“So the fact that we’ll have vaccines made in Canada that’s a good thing…it cuts down on supply chain issues” he said of Medicago. “If we start seeing variant specific vaccines at some point again….we could switch right away and start making the new sequence, as fast as other companies do.”
“So this is good news for sure,” Russell said.
Flight turbulence like that encountered by a Singapore Airlines flight on Tuesday is extremely common, but there's one aspect of severe turbulence an aviation expert says can lead to serious injury.
British Columbia serial killer Robert Pickton was attacked and sustained life-threatening injuries in a Quebec prison Sunday in what officials described as a 'major assault.'
New inflation data is 'welcome news' for consumers and an economist says it could signal the possibility for a interest rate cut as several core measures also continue to ease.
House of Commons Speaker Greg Fergus is facing fresh Conservative-led calls to resign, this time over "very partisan" and 'inflammatory' language used – the Liberals say mistakenly – to promote an upcoming event.
Ontario Provincial Police continue to investigate a long weekend fatal boat collision on Bobs Lake, north of Kingston, Ont.
In his latest column for CTVNews.ca, former NDP leader Tom Mulcair argues that if there's an unofficial frontrunner in the eventual race to replace Justin Trudeau as Liberal leader, it has to be former Bank of Canada governor Mark Carney.
The organizers of a month-long boycott of Loblaw-owned stores say they've decided to extend the boycott past May.
Donald Trump's reelection campaign called 'The Apprentice,' a film about the former U.S. president in the 1980s, 'pure fiction' and vowed legal action following its premiere at the Cannes Film Festival. But director Ali Abbasi is offering to privately screen the film for Trump.
The trial of a Winnipeg man who has admitted to killing four women has heard he searched the internet to look up the definition of what it means to be a serial killer.
Public libraries in Atlantic Canada are now lending a broader range of items.
Flashes of purple darting across the sky mixed with the serenading sound of songs will be noticed more with spring in full force in Manitoba.
Catching 'em all with impressive speed, a 7-year-old boy from Windsor, Ont. who only started his competitive Pokémon journey seven months ago has already levelled up to compete at a world championship level.
A sanctuary dedicated to animals with disabilities is celebrating the third birthday of one of its most popular residents.
2b Theatre recently moved into the old Video Difference building, seeking to transform it into an artistic hub, meeting space, and temporary housing unit for visiting performers in Halifax.
A B.C. woman says her service dog pulled her from a lake moments before she had a seizure, saving her life.
A Starbucks fan — whose name is Winter — is visiting Canada on a purposeful journey that began with a random idea at one of the coffee chain's stores in Texas.
Members of Piapot First Nation, students from the University of Winnipeg and various other professionals are learning new techniques that will hopefully be used for ground searches of potential unmarked grave sites in the future.
ALS patient Mathew Brown said he’s hopeful for future ALS patients after news this week of research at Western University of a potential cure for ALS.